LFVN icon

LifeVantage

11.13 USD
-0.59
5.03%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
11.25
+0.12
1.08%
1 day
-5.03%
5 days
-6.63%
1 month
-21.4%
3 months
-13.52%
6 months
-32.09%
Year to date
-36.98%
1 year
14.15%
5 years
-22.44%
10 years
118.66%
 

About: Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Employees: 238

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

77% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 22

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

7.16% more ownership

Funds ownership: 51.34% [Q1] → 58.5% (+7.16%) [Q2]

6% more funds holding

Funds holding: 105 [Q1] → 111 (+6) [Q2]

3% more capital invested

Capital invested by funds: $93.9M [Q1] → $96.3M (+$2.37M) [Q2]

89% less call options, than puts

Call options by funds: $64K | Put options by funds: $571K

Financial journalist opinion

Based on 7 articles about LFVN published over the past 30 days

Negative
Seeking Alpha
6 days ago
LifeVantage: Downgrading On Disappointing Results And Outlook - Hold
LifeVantage reported disappointing Q4/FY2025 results as domestic sales of the company's much-touted MindBody GLP-1 System came in below expectations. Following an impressive start, MindBody GLP-1 System sales have largely failed to ride the coattails of blockbuster weight-loss drugs like Wegovy and Zepbound. The company also issued FY2026 guidance below consensus expectations. At the mid-point of the provided revenue range, organic growth would be near zero.
LifeVantage: Downgrading On Disappointing Results And Outlook - Hold
Neutral
Seeking Alpha
9 days ago
LifeVantage Corporation (LFVN) Q4 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q4 2025 Earnings Call September 4, 2025 4:30 PM EDT Company Participants Steven Fife - President, CEO & Director Carl Aure - Chief Financial Officer Conference Call Participants Reed Anderson - ICR Inc. Douglas Lane - Water Tower Research LLC Presentation Operator Good day, ladies and gentlemen. Thank you for standing by.
LifeVantage Corporation (LFVN) Q4 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
9 days ago
LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025.
LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025
Neutral
GlobeNewsWire
10 days ago
LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness
Strategic acquisition expands network of Consultants, and strengthens LifeVantage's Activation differentiation in the rapidly growing gut health market Strategic acquisition expands network of Consultants, and strengthens LifeVantage's Activation differentiation in the rapidly growing gut health market
LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness
Neutral
GlobeNewsWire
11 days ago
LifeVantage to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the H.C. Wainwright 27th Annual Global Investment Conference, to be held September 8-10, 2025 in New York, NY.
LifeVantage to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Neutral
GlobeNewsWire
16 days ago
LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid September 16, 2025 to all stockholders of record at the close of business on September 8, 2025.
LifeVantage Declares Quarterly Dividend
Neutral
GlobeNewsWire
23 days ago
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025
SALT LAKE CITY, Aug. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2025, after the stock market closes on Thursday, September 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025
Neutral
GlobeNewsWire
1 month ago
LifeVantage To Open Iceland Market
SALT LAKE CITY, July 24, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced its upcoming launch into Iceland expected in September. This marks the company's continued partnership with its field leadership on international expansion and reinforces its commitment to delivering science-backed wellness solutions to consumers around the world.
LifeVantage To Open Iceland Market
Neutral
GlobeNewsWire
1 month ago
LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡
Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*‡ Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*‡
LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡
Positive
Seeking Alpha
1 month ago
The LifeVantage Advantage: High Retention, High Returns
LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN's growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream.
The LifeVantage Advantage: High Retention, High Returns
Charts implemented using Lightweight Charts™